Takeda Pharmaceuticals USA has entered an exclusive partnership with MiTest Health to expand the use of its Crohn’s disease risk (CD) prediction tool.
Developed by MiTest in 2014, the tool has been verified through review of a group of adult patients with CD and predictive modelling. However, it has been leveraged on a limited basis in clinical environments until now.
Through the partnership, the two companies aim to expand the use of CD risk prediction tool among gastroenterologists and their patients.
Dartmouth-Hitchcock Medical Centre IBD Centre section chief of gastroenterology and hepatology and co-director Corey Siegel said: “Crohn’s disease can cause severe complications and irreversible damage to the bowels.
“The tool has the potential to help tailor the approach for patients with Crohn’s disease by better informing them and their physicians about their individual potential risks for developing complications early on before disease complications occur.”
Typically, it is challenging to predict CD-associated complications such as fistulas, abscesses, strictures and intestinal obstruction.
The tool can identify the potential risk for disease progression using clinical phenotype information and a blood sample analysed for patient-specific serologic markers and NOD2 status.
It creates a graphical risk score and a visual report to facilitate healthcare providers to deliver personalised treatment in patients with CD.
Icahn School of Medicine Susan and Leonard Feinstein IBD Clinical Centre co-director Marla Dubinsky said: “Physicians using the validated predictive tool will be better able to support their patients with Crohn’s disease, who face significant challenges, by developing a disease management plan based on a shared understanding of their individual prognosis.
“We look forward to our continued work with Takeda to bring this important resource to physicians and patients.”